Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
5JUL

WHO lists first Bundibugyo Ebola test

2 min read
10:12UTC

WHO added the first molecular test for Bundibugyo virus to its Emergency Use Listing on 2 July, as testing across the affected provinces climbed past 2,000 samples a day.

← Back to Ebola's toolkit arrives, outbreak climbsJump to analysis ↓
ScienceDeveloping
Key takeaway

WHO listed the first Bundibugyo-specific diagnostic on 2 July as regional testing passed 2,000 samples a day.

WHO added the first molecular diagnostic for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL) on Thursday 2 July, the regulatory route that lets an unlicensed product be used in a crisis once WHO has vetted its quality and performance 1. No BDBV-specific test had ever been listed before. The test reads the virus's genetic material from a blood sample, and its listing matters because every unconfirmed suspected case is a person WHO might be infectious and untraced.

Testing capacity across the affected provinces has risen from roughly 200 to 400 tests a day at two facilities to more than 2,000 a day across a network of ten laboratories. "Timely access to quality-assured diagnostic tests can make a critical difference in containing transmission," said Dr Yukiko Nakatani, a WHO assistant director-general. The manufacturer was not named in the release.

WHO had to clear a testing backlog in June and recalibrate to confirmed-only reporting , so faster confirmation now closes a gap that had repeatedly made the outbreak's own headline count lurch rather than climb cleanly. The WHO R&D Blueprint, the programme that names priority pathogens, had flagged the missing Bundibugyo diagnostic as a gap in March, three months before the outbreak surfaced; that gap is now partly closed.

Deep Analysis

In plain English

A molecular diagnostic test looks for the virus's genetic material directly in a blood sample, which is faster and more specific than tests that look for antibodies the body makes later. Until 2 July, DRC labs testing for Bundibugyo ebolavirus relied on general-purpose Ebola tests not built for this specific strain, or had to send samples to a handful of central labs, causing delays. WHO's Emergency Use Listing is a fast-track approval process for tools urgently needed during an outbreak, used when there isn't time to wait for the years-long standard review. It let ten labs start using the new test immediately, pushing daily testing capacity from under 400 to over 2,000.

Deep Analysis
Root Causes

Point-of-care diagnostics for rare pathogens like Bundibugyo ebolavirus sit in what diagnostics developers call the valley of death: a manufacturer can recoup clinical-validation and EUL-submission costs only if a large, predictable market follows, and an outbreak-limited disease offers no such market once the emergency ends.

PATH and similar non-profit intermediaries typically bridge that gap by pre-negotiating volume guarantees, which is why WHO's Emergency Use Listing route exists at all: full prequalification review, built for commercial-scale products, cannot move fast enough for an active outbreak.

A test built specifically for Bundibugyo virus would also have flagged the French returnee case faster than the general Ebola serology assay used to confirm it in late June, since a species-specific PCR target returns a positive result before antibodies appear.

Sources:WHO
Mentions:Bundibugyo ebolavirus →WHO R&D Blueprint →DR Congo →Emergency Use Listing →World Health Organization →
First Reported In

Update #9 · Ebola's toolkit arrives, outbreak climbs

WHO· 5 Jul 2026
Read original →
Different Perspectives
Chinese health authorities
Chinese health authorities
China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.
US public health authorities
US public health authorities
CIDRAP and Dr Andrew Racine, president of the American Academy of Pediatrics, call 2026's 2,318 confirmed measles cases by 24 July the worst year since 1991's 2,126. Zero deaths against three in 2025 and a 7% hospitalisation rate, down from 11%, show record case counts have not brought record severity.
CEPI
CEPI
CEPI put an rVSV-platform vaccine candidate specific to Bundibugyo ebolavirus into trial-production on 31 July, developed by Hilleman Laboratories with MSD manufacturing and IAVI's reference virus, funded up to $8.5m. Eleven weeks into the third-largest Ebola outbreak on record, this is the first species-matched candidate; the licensed vaccine covers only Zaire ebolavirus.
Médecins Sans Frontières
Médecins Sans Frontières
MSF reports sexual-violence care in Ituri is almost non-existent, with 7 of 14 health centres closed or relocated by fighting, as Panzi Hospital logs 646 new survivors in six months, an 85% rise. Withdrawn US funding for post-exposure prophylaxis has left clinics across three provinces without PEP kits for months, a crisis running alongside Ebola, not caused by it.
DRC health workers at Elikya Ebola Treatment Centre
DRC health workers at Elikya Ebola Treatment Centre
Staff at DRC's Elikya Ebola Treatment Centre walked out on 25 July over unpaid wages, the second such action after Rwampara, while unconfirmed suspects occupy up to 64% of the country's isolation beds awaiting lab results. Workers are absorbing a response that has grown faster than its payroll and its labs.
Uganda's Ministry of Health
Uganda's Ministry of Health
Uganda's ministry says it discharged its last confirmed patient on 16 June, completed every contact's 21-day follow-up, and declared the country Ebola-free on 28 July, exactly 42 days later. It names Hon. Dr Chris Baryomunsi, Minister of Health, as overseeing a 20-case, 2-death outbreak it now considers closed.